FREMONT, Calif., April 26 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) today announced that it will host live webcasts in conjunction with the release of the company’s first quarter 2006 financial results on May 2 and its First Annual Business Update for the financial community on May 5. The Business Update will include a review of PDL’s three marketed products and future commercial opportunities.
First Quarter Financial Results
Financial results for PDL’s first quarter ended March 31, 2006 will be released following the close of the U.S. financial markets on Tuesday, May 2, 2006. PDL will hold a conference call to discuss these financial results, its commercial and clinical activities and its forward-looking information and guidance with respect to future results at 4:30 p.m. Eastern time on May 2, 2006. Participants on the call will include Mark McDade, Chief Executive Officer; Andrew Guggenhime, Senior Vice President and Chief Financial Officer; and Dr. Steven Benner, Senior Vice President and Chief Medical Officer.
A live webcast of the conference call will be available through the PDL website: www.pdl.com. Please access the website 15 minutes prior to the start of the live webcast to allow time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the company’s website approximately one hour after the conclusion of the call and will remain available for approximately 12 months after the call. An audio replay will also be available by telephone from approximately 6:30 p.m. Eastern time on May 2, 2006 through 6:30 p.m. Eastern time on May 9, 2006. To access the replay, dial 888-203-1112 from inside the United States and 719-457-0820 from outside the United States; enter conference ID number 6164043.
Financial and other information to be discussed in the call will be available in the “Investors” section of PDL’s website immediately prior to the commencement of the call.
First Annual Business Update
PDL BioPharma will also conduct a live webcast of its First Annual Business Update for the financial community to be held in New York City on Friday, May 5. A live webcast of the Business Update will be available at the PDL website, www.pdl.com, beginning at 8:00 a.m. Eastern time and is expected to conclude by 10:45 a.m. A replay, including the presentation materials, will be available on the company’s website approximately one hour after completion of the live webcast and will remain available for approximately 12 months after the webcast.
Participants from the company will include Mark McDade, Chief Executive Officer; David Iwanicki, Vice President, Sales and Sales Operations; Jaisim Shah, Senior Vice President, Marketing & Business Affairs; and John Gill, Senior Director, North American Marketing. They will provide a sales and marketing review of PDL’s three currently marketed products and a summary of future commercial opportunities. Senior Vice President and Chief Financial Officer Andrew Guggenhime and other members of management will be available for questions.
The Business Update will also include presentations by leading physicians in the areas of neurology, cardiology and oncology/transplant who will discuss the use of PDL’s marketed products in the acute-care hospital market.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering antibody humanization technology. Currently, PDL BioPharma’s diverse late-stage product pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical development for hepatorenal syndrome, autoimmune and inflammatory diseases, cardiovascular disorders and cancer. Further information on PDL BioPharma is available at http://www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
PDL BioPharma, Inc.
CONTACT: Ami Knoefler, Corporate and Investor Relations, +1-510-284-8851,or ami.knoefler@pdl.com, or Jim Goff, Investor Relations, +1-510-574-1421,or james.goff@pdl.com, both of PDL BioPharma, Inc.
Web site: http://www.pdl.com//
